SkinBioTherapeutics PLC
Research SkinBioTherapeutics PLC (SBTX) on Bullrun: market cap GBX 2.46B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSBTX
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 2.46B
- Financial periodFY2025
- RevenueGBP 4.64M
- Revenue growth283.7%
- Net income-GBP 696.25K
- Free cash flow-GBP 1.39M
- Gross margin61.6%
Valuation Snapshot
latest market cap is GBX 2.46B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 4.64M | -GBP 696.25K | -GBP 1.39M | 61.6% | 0 | GBP 4.78M | GBP 993.47K | GBP 9.42M |
| FY2024 | GBP 1.21M | -GBP 2.88M | -GBP 2.92M | 56.5% | -0.02 | GBP 800.90K | GBP 818.74K | GBP 2.97M |
| FY2023 | GBP 132.06K | -GBP 2.84M | -GBP 2.81M | 64.5% | -0.02 | GBP 1.31M | GBP 100.65K | GBP 1.99M |
| FY2022 | GBP 74.76K | -GBP 2.79M | -GBP 2.77M | 60.6% | -0.02 | GBP 1.80M | GBP 127.86K | GBP 2.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | GBX 2.46B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SkinBioTherapeutics PLC's market cap?
SkinBioTherapeutics PLC's market capitalization is GBX 2.46B.
What does SkinBioTherapeutics PLC do?
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.